
  
    
      
        
        
          
            
              “ Alchemy_NNP :_: a_DT process_NN of_IN transforming_VBG something_NN common_JJ into_IN something_NN
              special_JJ” —_NN Webster_NNP 's_POS Dictionary_NNP
            
          
        
        A_DT growing_VBG number_NN of_IN studies_NNS are_VBP reporting_VBG the_DT isolation_NN of_IN cardiac_JJ stem_NN cells_NNS from_IN a_DT
        variety_NN of_IN tissue_NN sources_NNS and_CC examining_VBG their_PRP$ effects_NNS on_IN promoting_VBG the_DT repair_NN of_IN the_DT
        injured_VBN heart_NN ._. In_IN the_DT current_JJ issue_NN of_IN 
        PLoS_NNP Biology_NNP ,_, the_DT storyline_NN takes_VBZ an_DT unexpected_JJ ,_, interesting_JJ twist_NN ,_, as_IN
        Neal_NNP Epstein_NNP and_CC his_PRP$ colleagues_NNS report_VBP the_DT isolation_NN of_IN a_DT novel_NN cell_NN type_NN from_IN skeletal_NN
        muscle_NN that_WDT can_MD adopt_VB a_DT highly_RB differentiated_JJ cardiac_JJ muscle_NN cell_NN phenotype_NN in_IN vitro_NN and_CC in_IN
        vivo_NN [_NN 1_CD ]_NN ._.
        In_IN this_DT study_NN ,_, the_DT authors_NNS use_VBP a_DT differential_NN isolation_NN procedure_NN to_TO remove_VB the_DT skeletal_NN
        muscle_NN cells_NNS and_CC myoblasts_NNS (_( immature_NN muscle_NN cells_NNS )_) ,_, and_CC then_RB collect_VB the_DT cells_NNS that_WDT are_VBP
        negative_JJ for_IN a_DT cell-surface_JJ marker_NN called_VBD Sca-_NNP 1_CD ._. Under_IN defined_VBN in_IN vitro_NN conditions_NNS ,_, these_DT
        cells_NNS adopt_VBP a_DT cardiomyocyte_NN phenotype_NN that_WDT goes_VBZ beyond_IN the_DT simple_JJ expression_NN of_IN
        cardiac-restricted_JJ biochemical_JJ and_CC molecular_JJ markers_NNS ,_, extending_VBG to_TO the_DT types_NNS of_IN single-cell_JJ
        physiological_JJ functions_NNS that_WDT are_VBP hallmarks_NNS of_IN authentic_JJ cardiomyocytes_NNS ,_, including_VBG action_NN
        potentials_NNS ,_, calcium_NN transients_NNS ,_, and_CC contractile_NN activity_NN ._. They_PRP call_VBP the_DT cells_NNS Spoc_NNP cells_NNS ,_,
        an_DT acronym_NN for_IN “ skeletal-based_JJ precursor_NN of_IN cardiomyocytes_NNS ._.”
        The_DT study_NN goes_VBZ on_IN to_TO show_VB that_IN these_DT cells_NNS can_MD adopt_VB this_DT phenotype_NN without_IN the_DT addition_NN
        of_IN cytokines_NNS or_CC agents_NNS such_JJ as_IN azacytidine_NN that_WDT are_VBP known_VBN to_TO activate_VBP the_DT muscle_NN gene_NN
        program_NN in_IN nonmuscle_NN cells_NNS ._. The_DT cells_NNS also_RB adopt_VBP the_DT cardiac_JJ phenotype_NN following_VBG their_PRP$ in_IN
        vivo_NN implantation_NN into_IN the_DT ischemic_JJ heart_NN following_VBG myocardial_NN infarction_NN ,_, suggesting_VBG a_DT
        potential_JJ therapeutic_JJ utility_NN for_IN these_DT cells_NNS ._. Since_IN Spoc_NNP cells_NNS were_VBD isolated_VBN from_IN murine_NN
        skeletal_NN muscle_NN ,_, they_PRP may_MD eventually_RB allow_VB the_DT use_NN of_IN sophisticated_JJ conditional_JJ genetic_JJ
        tracking_NN techniques_NNS to_TO monitor_VB the_DT migration_NN ,_, maturation_NN ,_, and_CC differentiation_NN of_IN the_DT cells_NNS
        in_IN the_DT in_IN vivo_NN context_NN ._.
        Of_IN course_NN ,_, a_DT study_NN with_IN results_NNS this_DT unexpected_JJ also_RB raises_VBZ a_DT number_NN of_IN intriguing_JJ
        questions_NNS ._. Identifying_NNP the_DT native_JJ location_NN of_IN Spoc_NNP cells_NNS ,_, as_RB well_RB as_IN the_DT in_IN vivo_NN niche_NN that_IN
        insulates_NNS them_PRP from_IN entering_VBG the_DT differentiated_JJ cardiac_JJ program_NN ,_, will_MD be_VB valuable_JJ ._. A_DT
        rigorous_JJ exploration_NN of_IN their_PRP$ developmental_NN origin_NN and_CC their_PRP$ relationship_NN to_TO the_DT other_JJ
        well-known_JJ cell_NN types_NNS in_IN skeletal_NN muscle_NN should_MD be_VB forthcoming_JJ ._. In_IN this_DT regard_NN ,_, a_DT set_NN of_IN
        skeletal_NN muscle_NN stem_NN cells_NNS ,_, distinct_JJ from_IN myoblasts_NNS ,_, has_VBZ also_RB been_VBN found_VBN [_NN 2_CD ]_NN ,_, and_CC the_DT
        question_NN arises_VBZ as_IN to_TO whether_IN Spoc_NNP cells_NNS are_VBP related_VBN to_TO these_DT other_JJ skeletal_NN muscle_NN
        progenitors_NNS ._.
      
      
        Cardiomyocyte_NNP Precursors_NNP Abound_NNP
        Other_JJ studies_NNS have_VBP reported_VBN the_DT isolation_NN of_IN cells_NNS that_WDT can_MD differentiate_VB into_IN cardiac_JJ
        muscle_NN from_IN diverse_JJ noncardiac_NN tissues_NNS ._. In_IN vitro_NN and_CC in_IN vivo_NN studies_NNS have_VBP suggested_VBN that_IN
        these_DT cells_NNS can_MD adopt_VB defined_VBN features_NNS of_IN the_DT cardiomyocyte_NN phenotype_NN when_WRB they_PRP are_VBP
        implanted_VBN into_IN injured_VBN heart_NN following_VBG myocardial_NN infarction_NN ._. It_PRP is_VBZ possible_JJ that_IN these_DT
        studies_NNS are_VBP pointing_VBG to_TO the_DT existence_NN of_IN a_DT rare_JJ circulating_VBG pool_NN of_IN precursor_NN cells_NNS ,_, which_WDT
        are_VBP able_JJ to_TO home_NN to_TO the_DT heart_NN ._.
        To_TO understand_VB the_DT provenance_NN of_IN these_DT cells_NNS ,_, it_PRP will_MD become_VB critical_JJ to_TO identify_VB a_DT set_NN
        of_IN gene_NN products_NNS ,_, or_CC markers_NNS ,_, that_WDT are_VBP restricted_VBN to_TO Spoc_NNP cells_NNS and_CC to_TO other_JJ potential_JJ
        progenitor_NN cells_NNS ._. Since_IN the_DT protocols_NNS for_IN the_DT isolation_NN of_IN the_DT Spoc_NNP cells_NNS have_VBP been_VBN
        developed_VBN in_IN the_DT mouse_NN ,_, it_PRP should_MD also_RB become_VB possible_JJ to_TO use_VB state-of-the-art_JJ spatial_NN and_CC
        temporal_JJ control_NN strategies_NNS for_IN triggering_VBG irreversible_JJ lineage_NN tracers_NNS in_IN these_DT cells_NNS in_IN
        the_DT in_IN vivo_NN context_NN without_IN isolating_VBG the_DT cells_NNS per_IN se_FW ._. This_DT will_MD make_VB it_PRP possible_JJ to_TO
        follow_VB the_DT fate_NN of_IN these_DT cells_NNS as_IN they_PRP differentiate_VB ._. Similar_JJ approaches_NNS have_VBP recently_RB been_VBN
        used_VBN to_TO identify_VB a_DT subset_NN of_IN rare_JJ ,_, native_JJ cardiac_JJ progenitors_NNS (_( which_WDT are_VBP positive_JJ for_IN the_DT
        marker_NN Islet-_NNP 1_LS )_) in_IN the_DT newborn_JJ hearts_NNS of_IN mice_NNS ,_, rats_NNS ,_, and_CC humans_NNS (_( Figure_NN 1_CD ;_: [_NN 3_CD ]_NN )_) ._. Exploring_NNP
        the_DT relationship_NN of_IN the_DT Spoc_NNP cells_NNS to_TO these_DT native_JJ cardioblasts_NNS could_MD reveal_VB shared_VBN
        pathways_NNS that_WDT drive_NN their_PRP$ formation_NN ,_, renewal_NN ,_, and_CC differentiation_NN ._.
      
      
        Defining_VBG a_DT True_NNP Progenitor_NNP
        One_CD of_IN the_DT inherent_JJ caveats_NNS of_IN the_DT present_JJ study_NN is_VBZ the_DT potential_NN for_IN phenotypic_JJ drift_NN
        that_WDT occurs_VBZ with_IN prolonged_JJ growth_NN of_IN any_DT cell_NN type_NN ._. It_PRP is_VBZ possible_JJ ,_, for_IN example_NN ,_, that_IN the_DT
        genetic_JJ program_NN of_IN these_DT cells_NNS gradually_RB changes_VBZ with_IN time_NN such_JJ that_IN they_PRP can_MD more_RBR easily_RB
        adopt_VB the_DT cardiac_JJ phenotype_NN ._. Heart_NNP and_CC skeletal_NN muscle_NN share_NN many_JJ key_JJ gene_NN regulatory_JJ
        factors_NNS and_CC downstream_JJ genetic_JJ programs_NNS ,_, and_CC the_DT loss_NN of_IN a_DT few_JJ key_JJ negative_JJ regulatory_JJ
        checkpoints_NNS might_MD allow_VB the_DT cells_NNS to_TO differentiate_VB towards_IN a_DT cardiac_JJ phenotype_NN ._. Again_RB ,_,
        documenting_VBG the_DT existence_NN of_IN these_DT cells_NNS in_IN the_DT in_IN vivo_NN context_NN ,_, particularly_RB during_IN stages_NNS
        of_IN embryonic_JJ myogenesis_NNS ,_, will_MD be_VB key_JJ ._.
        There_EX is_VBZ already_RB a_DT clear_JJ precedent_NN for_IN this_DT type_NN of_IN phenotypic_JJ drift_NN between_IN cardiac_JJ and_CC
        skeletal_NN muscle_NN ._. H_NNP 9_CD c_SYM 2_CD cells_NNS were_VBD originally_RB derived_VBN from_IN rat_NN heart_NN ,_, but_CC actually_RB represent_VB
        skeletal_NN myoblasts_NNS ,_, because_IN they_PRP fuse_NN and_CC form_NN myotubes_NNS following_VBG serum_NN withdrawal_NN ._. These_DT
        cells_NNS express_VBP myogenic_JJ factors_NNS in_IN the_DT MyoD_NNP family_NN ,_, and_CC do_VBP not_RB express_VB cardiac-restricted_JJ
        factors_NNS ._. Although_IN the_DT cells_NNS were_VBD initially_RB isolated_VBN on_IN the_DT basis_NN of_IN their_PRP$ expression_NN of_IN
        cardiac_JJ markers_NNS ,_, this_DT is_VBZ an_DT example_NN phenotypic_JJ drift—that_NN is_VBZ ,_, the_DT cells_NNS have_VBP drifted_VBD from_IN a_DT
        cardiac_JJ phenotype_NN during_IN repeated_VBN passage_NN rather_RB than_IN simply_RB representing_VBG skeletal_NN muscle_NN
        cells_NNS resident_NN within_IN the_DT heart_NN ._. Thus_RB ,_, the_DT isolation_NN of_IN an_DT immature_NN cell_NN from_IN a_DT heart_NN does_VBZ
        not_RB necessarily_RB denote_NN that_IN it_PRP is_VBZ serving_VBG as_IN a_DT cardiac_JJ progenitor_NN or_CC stem_VB cell_NN ._. Potentially_NNP
        the_DT same_JJ issue_NN might_MD hold_VB for_IN putative_JJ cardiac_JJ progenitor_NN cells_NNS isolated_VBN from_IN skeletal_NN
        muscle_NN ,_, where_WRB the_DT phenotype_NN observed_VBD may_MD not_RB necessarily_RB reflect_VB its_PRP$ role_NN in_IN vivo_NN within_IN
        skeletal_NN muscle_NN ._.
        One_CD of_IN the_DT difficulties_NNS with_IN alchemy_NN and_CC this_DT new_JJ age_NN of_IN cardiac_JJ myocyte_NN biology_NN is_VBZ
        related_VBN to_TO defining_VBG a_DT rigorous_JJ set_NN of_IN criteria_NNS that_WDT allow_VBP one_CD to_TO make_VB the_DT claim_NN that_IN the_DT
        cell_NN type_NN of_IN interest_NN is_VBZ truly_RB a_DT cardiac_JJ progenitor_NN or_CC stem_VB cell_NN and_CC is_VBZ acquiring_VBG a_DT fully_RB
        differentiated_JJ phenotype_NN [_NN 4_CD ]_NN ._. In_IN this_DT regard_NN ,_, the_DT paper_NN by_IN Epstein_NNP and_CC colleagues_NNS has_VBZ done_VBN
        an_DT admirable_JJ job_NN of_IN scoring_VBG for_IN functional_JJ phenotypes_NNS (_( for_IN example_NN ,_, having_VBG action_NN
        potentials_NNS and_CC calcium_NN transients_NNS )_) that_WDT are_VBP far_RB beyond_IN the_DT simple_JJ expression_NN of_IN cardiac_JJ
        muscle_NN markers_NNS ,_, which_WDT has_VBZ been_VBN the_DT phenotypic_JJ endpoint_NN for_IN many_JJ previous_JJ papers_NNS in_IN the_DT
        field_NN ._. In_IN addition_NN ,_, the_DT authors_NNS go_VBP on_IN to_TO show_VB the_DT acquisition_NN of_IN the_DT differentiated_JJ cardiac_JJ
        phenotype_NN in_IN the_DT in_IN vivo_NN state_NN in_IN the_DT absence_NN of_IN fusion_NN with_IN neighboring_VBG cardiac_JJ muscle_NN
        cells_NNS ,_, which_WDT has_VBZ been_VBN a_DT confounding_VBG variable_JJ in_IN most_JJS other_JJ studies_NNS of_IN this_DT type_NN ._. If_IN a_DT
        precursor_NN cell_NN simply_RB fuses_NNS with_IN a_DT fully_RB differentiated_JJ cell_NN in_IN a_DT tissue_NN ,_, one_PRP could_MD easily_RB
        be_VB fooled_VBN into_IN thinking_VBG that_IN the_DT precursor_NN has_VBZ itself_PRP differentiated_JJ ,_, as_IN has_VBZ been_VBN found_VBN for_IN
        many_JJ types_NNS of_IN putative_JJ cardiac_JJ stem_NN cells_NNS [_NN 5_CD ]_NN ._. Fortunately_RB ,_, techniques_NNS have_VBP been_VBN devised_VBN to_TO
        detect_VB such_JJ events_NNS ._.
        In_IN surveying_VBG the_DT growing_VBG number_NN of_IN studies_NNS and_CC claims_NNS of_IN new_JJ cells_NNS that_WDT can_MD acquire_VB some_DT
        type_NN of_IN heart_NN cell_NN phenotype_NN in_IN vitro_NN or_CC in_IN vivo_NN (_( for_IN a_DT review_NN see_VB [_NN 6_CD ]_NN )_) ,_, it_PRP will_MD become_VB
        increasingly_RB important_JJ to_TO create_VB a_DT set_NN of_IN rigorous_JJ criteria_NNS that_WDT would_MD distinguish_VB between_IN
        the_DT following_VBG :_: authentic_JJ progenitor_NN cells_NNS that_WDT are_VBP already_RB committed_VBN to_TO the_DT cardiac_JJ
        lineage_NN ;_: pluripotent_NN stem_NN cells_NNS that_WDT can_MD infrequently_RB adopt_VB the_DT cardiac_JJ phenotype_NN ;_:
        phenotypic_JJ drift_NN of_IN other_JJ muscle_NN progenitors_NNS with_IN an_DT increased_VBN propensity_NN to_TO enter_VB cardiac_JJ
        lineages_NNS ;_: and_CC a_DT variety_NN of_IN other_JJ cell_NN types_NNS that_WDT can_MD aberrantly_RB express_VB cardiac_JJ markers_NNS
        ectopically_RB or_CC by_IN fusion_NN with_IN neighboring_VBG cardiac_JJ muscle_NN cells_NNS ._.
        Finding_VBG cell-type-specific_JJ markers_NNS for_IN these_DT cells_NNS will_MD be_VB critical_JJ ,_, as_IN opposed_VBN to_TO
        generalized_JJ markers_NNS that_WDT do_VBP not_RB allow_VB the_DT in_IN vivo_NN discrimination_NN of_IN their_PRP$ precise_JJ
        localization_NN ,_, mobilization_NN ,_, and_CC differentiation_NN in_IN the_DT intact_JJ muscle_NN ._. The_DT gold_NN standard_JJ
        would_MD then_RB become_VB the_DT isolation_NN of_IN the_DT cells_NNS from_IN the_DT intact_JJ organ_NN after_IN differentiation_NN
        has_VBZ occurred_VBN by_IN creating_VBG genetically_RB based_VBN or_CC antibody-based_JJ approaches_NNS to_TO identify_VB and_CC /_NN or_CC
        purify_NN the_DT already_RB differentiated_JJ progeny_NN from_IN the_DT intact_JJ muscle_NN ._. Alternatively_RB ,_, new_JJ
        two-photon_JJ confocal_NN microscopy_NN approaches_NNS to_TO identify_VB the_DT cells_NNS and_CC then_RB to_TO monitor_VB cardiac_JJ
        function_NN in_IN the_DT intact_JJ heart_NN should_MD prove_VB valuable_JJ [_NN 7_CD ]_NN ._.
        For_IN two_CD decades_NNS ,_, the_DT bulk_NN of_IN our_PRP$ knowledge_NN of_IN molecular_JJ pathways_NNS that_WDT guide_NN cardiac_JJ
        growth_NN ,_, development_NN ,_, and_CC disease_NN has_VBZ been_VBN gleaned_VBN from_IN a_DT combination_NN of_IN in_IN vivo_NN studies_NNS in_IN
        genetically_RB engineered_VBN mice_NNS and_CC primary_JJ cultures_NNS of_IN neonatal_NN and_CC adult_NN rat_NN cardiomyocytes_NNS ._.
        Perhaps_RB the_DT most_RBS scientifically_RB exciting_JJ aspect_NN of_IN this_DT new_JJ age_NN of_IN cardiomyocyte_NN biology_NN is_VBZ
        not_RB simply_RB related_VBN to_TO cardiac_JJ repair_NN ._. To_TO date_NN ,_, there_EX have_VBP been_VBN no_DT continuous_JJ differentiated_JJ
        cardiac_JJ cell_NN lines_NNS ,_, a_DT fact_NN that_WDT has_VBZ hampered_VBN the_DT field_NN for_IN decades_NNS ._. The_DT development_NN of_IN
        well-characterized_JJ cardiac_JJ progenitor_NN cells_NNS offers_VBZ the_DT promise_NN of_IN using_VBG real_JJ genetic-based_JJ
        approaches_NNS to_TO rapidly_RB define_VB the_DT complex_JJ pathways_NNS that_WDT guide_NN cardiac_JJ contractility_NN ,_,
        excitability_NN ,_, and_CC lineage_NN diversification_NN into_IN atrial_NN ,_, ventricular_NN ,_, and_CC conduction_NN system_NN
        myocyte_NN cell_NN lineages_NNS ._.
      
    
  
